In Bevacizumab to Aflibercept Switch, Monitor For Risks - Endocrinology Advisor
Patients switching from bevacizumab to aflibercept for DME therapy should be evaluated for several risk factors.
Source: endocrinologyadvisor.com
Retina Network Protocol News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Retina Network Protocol. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Retina Network Protocol Today - Breaking & Trending Today
Medication Cost Drives Expenses in Diabetic Macular Edema Treatment
The analysis of the DRCR Retina Network Protocol AC suggested cost savings occur with bevacizumab-first step therapy in eyes with DME, but the magnitude might not be as great as previously understood.
Source: hcplive.com
Switching From Aflibercept to Bevacizumab Results in Cost Savings Without Sacrificing Visual Acuity, Says Dr Jennifer Sun
The Protocol AC study analyzed visual acuity gains and cost if patients with diabetic macular edema started on bevacizumab, which costs less, and switched to aflibercept later, explained Jennifer K. Sun, MD, MPH, associate professor of ophthalmology and chief of the Center for Clinical Eye Research and Trials, Harvard Medical School; and chair, DRCR Retina Network.
Source: ajmc.com
Ultra-widefield imaging yields predictive data for diabetic retinopathy worsening
KOLOA, Hawaii — Ultra-widefield fluorescein angiography may enable more sensitive and specific methods to predict diabetic retinopathy worsening compared with standard FA, Paolo S. Silva, MD, said at Retina 2023.
Source: healio.com
Step Therapy Succeeds for Diabetic Macular Edema
No difference in visual acuity at 2 years with bevacizumab-first or upfront-aflibercept strategy
Source: medpagetoday.com